# Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT07562152** · PHASE3 · RECRUITING · sponsor: **Immuneering Corporation** · enrollment: 510 (estimated)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Atebimetinib
- **DRUG:** GnP
- **DRUG:** mGnP

## Key facts

- **NCT ID:** NCT07562152
- **Lead sponsor:** Immuneering Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-06
- **Final completion:** 2029-02
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07562152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07562152, "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07562152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*